Home  »  Companies   »  Can Adc Therapeutics SA (NYSE:ADCT) Stock Be A Goo...

Can Adc Therapeutics SA (NYSE:ADCT) Stock Be A Good Mid-Term Investment?

Adc Therapeutics SA (NYSE:ADCT) price closed higher on Friday, February 09, jumping 4.36% below its previous close.

A look at the daily price movement shows that the last close reads $5.00. The company’s 5Y monthly beta was ticking 1.58. Taking into account the 52-week price action we note that the stock hit a 52-week high of $4.57 and 52-week low of $0.36. The stock added 100.00% on its value in the past month.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Adc Therapeutics SA, which has a market valuation of $351.59 million, is expected to release its quarterly earnings report Feb 26, 2024 – Mar 02, 2024. Analysts tracking ADCT have forecast the quarterly EPS to shrink by -0.46 per share this quarter, while the same analysts predict the annual EPS to hit -$2.35 for the year 2024 and up to -$1.88 for 2024. In this case, analysts estimate an annual EPS growth of -18.10% for the year and 20.00% for the next year.

On average, analysts have forecast the company’s revenue for the quarter will hit $14.98 million, with the likely lows of $10.76 million and highs of $17 million. The average estimate suggests sales growth for the quarter will likely fall by -78.50% when compared to those recorded in the same quarter in the last financial year. Staying with the analyst view, there is a consensus estimate of $67.95 million for the company’s annual revenue in 2023. Per this projection, the revenue is forecast to grow -67.60% below that which the company brought in 2023.

Revisions to the company’s EPS highlights a short term direction of a stock’s price movement, which in the last 7 days came up with 1 upward and no downward reviews. On the technical perspective front, indicators give ADCT a short term outlook of 100% Buy on average. Looking at the stock’s medium term indicators we note that it is averaging as a 100% Buy, while an average of long term indicators are currently assigning the stock as 50% Buy.

The overview shows that ADCT’s price is at present 8.52% off the SMA20 and -81.01% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 82.89, with weekly volatility standing at 11.30%. The indicator jumps to 12.19% when calculated based on the past 30 days. Adc Therapeutics SA (NYSE:ADCT)’s beta value is holding at 1.62, while the average true range (ATR) indicator is currently reading 0.35.

Turning out attention to how the Adc Therapeutics SA stock has performed in comparison to its peers in the industry, here’s what we find: ADCT’s stock is 4.36% on the day and -0.91% in the past 12 months, while Eli Lilly & Co. (LLY) traded 0.61%% in the last session and was positioned 114.46% up on its price 12 months ago. Turning out attention to how the Adc Therapeutics SA stock has performed in comparison to its peers in the industry, here’s what we find: ADCT’s stock is 4.36% on the day and -0.91% in the past 12 months, while Eli Lilly & Co. (LLY) traded 0.61%% in the last session and was positioned 114.46% up on its price 12 months ago. Another comparison is with AbbVie Inc. (ABBV) whose stock price was down -0.41%% in the last trading session, and has flourished 14.49% over the past year. Also, AstraZeneca PLC ADR (AZN) showed down trend of -1.98%% while its price kept floating at -9.61% over the past year.

An analysis of the Adc Therapeutics SA (NYSE:ADCT) stock in terms of its daily trading volume indicates that the 3-month average is 1.66. However, this figure increases on the past 10-day timeline to an average of 1.3 million.

Current records show that the company has 80.64M in outstanding shares. The insiders’ percentage holdings are 32.29% of outstanding shares while the percentage share held by institutions stands at 48.38%. The stats also highlight that short interest as of Jan 31, 2024, stood at 2.93 million shares, which puts the short ratio at the time at 3.08. From this we can glean that short interest is 3.63% of company’s current outstanding shares. Notably, we see that shares short in January fall slightly given the previous month’s figure stood at 3.72 million. But the 162.65% upside, the stock’s price has registered year-to-date as of last trading, will likely reignite investor interest given the prospect of it rallying even higher.